- Ms. Austin assumes role from Glenn F. Tilton, who will
continue to serve as an independent director
NORTH
CHICAGO, Ill., June 20,
2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today
announced that the independent directors of the board have selected
Roxanne S. Austin as lead
independent director, effective July 1,
2024. Ms. Austin succeeds Glenn F.
Tilton, who has served as lead independent director since
2013. Mr. Tilton will continue to serve on the AbbVie Board as an
independent director.
"One of AbbVie's greatest strengths is an experienced, diverse
and highly independent Board of Directors committed to the highest
standards of corporate governance," said Richard A. Gonzalez, chairman and chief
executive officer, AbbVie. "The appointment of Roxanne as lead
independent director reflects a thorough and deliberate process by
the independent directors of the Board, who strongly believe that
her experience and leadership ability make her highly qualified to
lead the AbbVie Board. Roxanne has provided keen insights and
guidance as an independent director since joining the Board in
2013. I'm delighted that she will bring her expertise to us in this
role, especially as we make the important transition in executive
leadership when Rob Michael assumes
the role of AbbVie's CEO on July
1."
"I've always valued Glenn's counsel and leadership as lead
independent director," continued Mr. Gonzalez. "Glenn has made
immeasurable contributions to our strategy, financial success and
corporate governance, and his presence in AbbVie's boardroom has
clearly elevated all of us. I look forward to continuing to work
alongside him."
"The independent directors of AbbVie were unanimous in their
support for Roxanne as the new lead independent director of the
Board," commented Mr. Tilton. "She will provide thoughtful
strategic leadership to the company and will work diligently to
ensure AbbVie continues to deliver results to all our stakeholders
with passion and integrity. It has been extremely rewarding to
serve as the lead independent director at AbbVie for the past 11
years. I am excited for the company's future and am pleased to
continue working with Roxanne, Rick, Rob and the rest of AbbVie's
Board to build on the company's success."
"I am honored to have received the support of AbbVie's Board in
this important role, and I am excited to partner with the Board and
management team as we embark on this important next phase in
AbbVie's growth," said Ms. Austin. "I would like to thank Glenn for
his invaluable guidance as an independent director for many years.
His leadership has been marked by integrity, intelligence and
determination, and AbbVie will benefit tremendously by his
continued service on the Board."
About Roxanne S.
Austin
Ms. Austin is president of Austin Investment Advisors, a private
investment and consulting firm. She chaired the U.S. Mid-market
Investment Advisory Committee of EQT Partners from 2017 to 2023.
Previously, Ms. Austin also served as the president and chief
executive officer of Move Networks, Inc., a provider of Internet
television services. Ms. Austin served as president and chief
operating officer of DIRECTV, Inc. Ms. Austin also served as
executive vice president and chief financial officer of Hughes
Electronics Corporation and as a partner of Deloitte & Touche
LLP. Ms. Austin is also a director of Crowdstrike, Inc.,
Freshworks, Inc., and Verizon Communications Inc. Ms. Austin
previously served as a director of Abbott Laboratories from 2000 to
2022, Teledyne Technologies, Inc. from 2006 to 2021, Target
Corporation from 2002 to 2020, and Telefonaktiebolaget LM Ericsson
from 2008 to 2016.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
and solutions that solve serious health issues today and address
the medical challenges of tomorrow. We strive to have a remarkable
impact on people's lives across several key therapeutic areas –
immunology, oncology, neuroscience and eye care – and products and
services in our Allergan Aesthetics portfolio. For more information
about AbbVie, please visit us at www.abbvie.com.
Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly
Twitter) and YouTube.
AbbVie Forward-Looking Statements
Some statements in this news release are, or may be
considered, forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project" and similar expressions and uses
of future or conditional verbs, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those expressed or implied in the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, challenges to intellectual property,
competition from other products, difficulties inherent in the
research and development process, adverse litigation or government
action, and changes to laws and regulations applicable to our
industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2023 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation, and specifically declines, to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abbvie-appoints-roxanne-s-austin-as-lead-independent-director-of-the-board-of-directors-302177385.html
SOURCE AbbVie